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Abstract
Background: There is increasing interest in the use of eliciting doses (EDs) to inform
allergen risk management. The ED can be estimated from the distribution of threshold
doses for allergic subjects undergoing food challenges within a specified population.
Estimated ED05 values for cow's milk (the dose expected to cause objective allergic
symptoms in 5% of the milk-allergic population) range from 0.5 mg to 13.9 mg cow's
milk protein. We undertook a single-dose challenge study to validate a predicted ED05
for cow's milk of 0.5 mg protein.
Methods: Participants were recruited from 4 clinical centres. Predetermined criteria
were used to identify patients reacting to 0.5 mg cow's milk protein (approximately
0.015 mL of fresh cow's milk). Children over 1 year underwent formal challenge to
cow's milk to confirm clinical reactivity.
Results: 172 children (median age 6.0 (IQR 0.7-11) years, 57% male) were included
in this analysis. Twelve (7.0%, 95% CI 3.7%-11.9%) children experienced objective
symptoms that met the predetermined criteria. One participant had mild anaphylaxis

Abbreviations: CMPA, Cow's milk protein allergy; DBPCFC, Double-blind placebo-controlled food challenge; ED, Eliciting dose; IQR, Interquartile range; OFC, Oral food challenge;
VITAL, Voluntary Incidental Trace Allergen Labelling.
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that responded to a single dose of adrenaline, the remainder experienced only mild
symptoms with no treatment required. We did not identify any baseline predictors of
sensitization that were associated with objective reactivity to the single-dose challenge using 0.5 mg cow's milk protein.
Conclusions: These data support an estimated ED05 for cow's milk of 0.5 mg protein.
Values for ED05 above 0.5 mg for cow's milk protein proposed for allergen risk management need to be reviewed.
KEYWORDS

cow's milk, eliciting dose, single-dose challenge, thresholds, Voluntary Incidental Trace
Allergen Labelling (VITAL)

Key Message
In this multicentre study, we validated the eliciting dose (ED) for cow's milk at around 0.5 mg
cow's milk protein (ED 05), and thus, higher estimates currently proposed to inform allergen risk
management should be reviewed.

Editor: Motohiro Ebisawa

1 | I NTRO D U C TI O N

fatalities in children,11 a pattern that has also been noted in North
America and Israel.12-14 This is probably due to a combination of

There is increasing interest in the use of routinely collected clinical

factors: milk as an ingredient that is ubiquitous in our diets; milk

data from oral food challenges (OFC) to inform both patient manage-

as a high protein food; and lower levels of awareness amongst the

ment and allergen risk management in industry, in terms of the level

public and food business operators that CMPA can cause severe

of dietary allergen avoidance required. Eliciting doses (ED) for allergic

reactions.15 Reported estimated ED 05 values for cow's milk in the

reactions in 1% and/or 5% of the allergic population (ED01 and ED05,

literature range from 0.21 mg to 13.9 mg cow's milk protein. 2,7,16,17

respectively) can be used to inform ‘reference doses’, indicating a level

This variation may be partly explained by differences in patient

of allergen presence above which additional risk management strate-

selection, with some studies including younger patients (many of

gies (such as precautionary allergen labelling) are required to protect

whom may be at various stages of outgrowing their milk allergy) or

the allergic population.1,2 In addition, it has been proposed that di-

with lower levels of sensitization, which has been associated with

etary advice to food-allergic consumers might be individualized if a

higher levels of reactivity at challenge.17 We have previously used

particular level of tolerance can be demonstrated at clinical OFC.3,4

a novel, single-d ose challenge design to validate the ED 05 for pea-

5

ED values are generated from OFC data, but many OFC proto-

nut. 3 In this study, we sought to replicate this method in children

cols use a starting dose that will trigger symptoms in a significant

with cow's milk protein allergy (CMPA), to assess whether current

proportion of patients. For example, the PRACTALL consensus rec-

estimates for ED 05 for cow's milk are valid in terms of allergen risk

ommends a starting dose of 3 mg food protein for OFC,6 but data

management.

suggest that for cow's milk protein allergy (CMPA), this may cause
objective symptoms in 10% of allergic individuals.7 Thus, these data
are ‘left-censored’ and cause greater uncertainty when estimating

2 | M E TH O DS

a level of exposure, which causes symptoms in a small proportion
of the allergic population.5 Conventional protocols, which use in-

This was a multicentre study that incorporated children with

cremental doses given every 20-30 minutes also make it difficult to

CMPA recruited from 4 clinical centres: Imperial College

reliably determine the precise dose that has triggered symptoms, but

London—St Mary's Hospital, UK (Imperial); Hospital Clinico San

this uncertainty can be reduced by using both discrete and cumula-

Carlos (HCSC) and Hospital Universitario Infantil Niño Jesús

8

tive doses to estimate ED values. In addition, relying on OFC un-

(NJH) in Madrid, Spain; and Cork University Hospital, Ireland

dertaken in routine clinical practice can result in selection bias, since

(CUH); the specific cohorts are described in Table 1. Exclusion

subjects at high likelihood of true clinical reactivity or with a history

criteria were as follows: medically unfit for challenge according to

of prior anaphylaxis may be excluded.6

local unit OFC guidelines/protocol (eg high fever or unwell with

CMPA is a major cause of severe and even fatal allergic re-

intercurrent illness); acute wheeze or poorly controlled asthma

actions.9,10 Data from the United Kingdom have found that cow's

symptoms (as defined by clinician judgement with reference to

milk is the confirmed trigger in over a quarter of anaphylaxis

the ICON consensus18) or oral corticosteroids within 14 days of

1058
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Characteristics of included cohorts

Centre

Ireland

Madrid, Spain

United Kingdom

Cork University Hospital
(CUH)

Hospital Clinico San Carlos
(HCSC)

Hospital Universitario
Infantil Niño Jesús (NJH)

Imperial College
London (Imperial)

Inclusion criteria

History of unequivocal exposure (including accidental) and
typical acute allergic reaction within the preceding 2 mo and
evidence of IgE sensitization (SPT or sIgE) to cow's milk.
OR
Positive OFC to cow's milk within 2 mo of the single-dose
challenge.

History consistent with IgE-mediated allergy to CM
and
Positive DBPCFC to cow's milk immediately
following single-dose challenge.

Inclusion age:

0-16 y

Any

6-17 y

Challenge formulation:

>1 y: Milk powder
incorporated into a
chocolate dessert matrix
<1 y: Fresh cow's milk

Milk powder incorporated
into a chocolate dessert
matrix

Milk powder dissolved in rice “milk” as part of a
DBPCFC

Blinding for single-dose
challenge

Open

Open

Double-blind

Observation period:

2h

2h

Minimum 1 h post-dose, with no objective
symptoms within 2 h

Clinical reactivity
confirmed by:

>1 y: open OFC
<1 y: allergic reaction within
2m of assessment and IgE
sensitization

Objective symptoms at oral
exposure to cow's milk
(eg OFC, DBPCFC) under
medical supervision

Objective symptoms at DBPCFC

OFC; anaphylaxis of any cause in the 4 weeks prior to OFC (to
exclude patients in an anergic state); and antihistamines within

2.2 | Criteria for a positive OFC result and
case definition

5 days of OFC. In order to minimize selection bias, routine clinic
lists were screened for patients with IgE-m ediated allergy to

Data collection and case definitions have been previously de-

cow's milk, and then, participation discussed with all potentially

scribed. 3 In brief, detailed notes were taken recording all physi-

suitable participants and their families during routine clinic ap-

cal or behavioural changes observed or self-reported during the

pointments. Subjects with a history of prior anaphylaxis were

single-dose OFC. Predetermined objective criteria were used,

not excluded. The studies were registered at Clinicaltrials.gov
(NCT02216175, NCT02295397).

since published ED 05 values are predicted on the basis of challenge-

associated objective symptoms only.1-6 The predetermined objec-

tive criteria for a positive single-dose OFC result were as follows:

2.1 | Food challenge

3 or more concurrent wheals of non-contact urticaria persisting
for at least 5 minutes; perioral or periorbital angioedema; rhinoconjunctivitis (including sneezing) for at least 5 minutes; diarrhoea;

Protocols were aligned across the 4 centres in order to obtain the

vomiting (excluding gag reflex); or anaphylaxis (with evidence of

same clinical data following 0.5 mg cow's milk protein (approximately

circulatory or respiratory compromise, such as persistent cough,

0.015 mL of fresh cow's milk) administered as a single dose, using the

wheeze, change in voice, stridor, difficulty breathing, and col-

same predefined case definition for objective allergic symptoms. In

lapse). 20 Transient objective symptoms (rhinoconjunctivitis <5 min-

general, the single-dose challenge was administered as milk powder

utes, transient mild erythema) were excluded. Subjective symptoms

incorporated into an allergen-free chocolate dessert matrix (previously

were also recorded. Following completion of the clinical studies,

validated for double-blind challenges19) or dissolved into flavoured rice

cases were reviewed by at least 2 senior independent investigators

‘milk’ (Table 1). In participants under age 1 year at CUH, the dose was

and the above criteria were applied to define OFC which met these

instead administered as diluted (1:7) fresh milk using a syringe (to re-

predetermined objective criteria.

duce the risk of a contact reaction to the lips). Routine OFC monitoring
was undertaken according to local practice. At two centres (Imperial
and NJH), formal DBPCFC were conducted, where the 0.5 mg dose

2.3 | Confirmation of clinical reactivity to cow's milk

constituted the first dose of the OFC; subjects were observed for at
least 1 hour prior to the next challenge dose being administered (and

In order to avoid the possibility of including participants without

longer if there were any non-transient symptoms). At HCSC and CUH,

CMPA, clinical reactivity was confirmed in participants over 1 year

subjects underwent a single (unblinded) administration of 0.5 mg pro-

of age at formal oral exposure, typically double-b lind placebo-

tein and were observed for at least 2 hours thereafter.

controlled

challenge

conducted

according

to

international

|
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PRACTALL consensus criteria, 6 although some families declined

cow's milk protein. Ten individuals went on to pass a formal food

DBPCFC and instead underwent an unblinded challenge under

challenge (ie did not react to a minimum of 250 mL cow's milk) fol-

medical supervision, which required objective symptoms to be

lowing the 0.5 mg challenge and were therefore excluded from the

assigned as ‘positive’. Infants (under 12 months) did not undergo

primary analysis. Baseline demographics are shown in Table 2. The

OFC, but were included on the basis of physician-diagnosed aller-

clinical centre in Ireland predominantly recruited children under age

gic reaction within 2 months of assessment and IgE sensitization

1 year with CMPA, HCSC recruited infants with new diagnosis of

to milk.

CMPA as well as patients over age 1 year with an existing diagnosis of CMPA, while other centres recruited children with persistent

2.4 | IgE sensitization

CMPA. Overall, 61 (34%) of the cohort were under age 1 year (recruited at CUH and HCSC); participants at NJH and Imperial were
older (P < .001, Kruskal-Wallis test). IgE sensitization was similar

Blood samples were collected from participants prior to OFC.

across all 4 cohorts in terms of skin prick test wheal, but serum IgE

Samples were processed according to the manufacturers’ instruc-

to cow's milk was lower in the CUH cohort (P = .04), but equivalent

tions and snap-frozen at −80°C until analysis. Specific IgE to cow's

across the other 3 cohorts (P = .10), reflecting the lower age of the

milk and casein was measured using ImmunoCAP (Thermo Fisher

included participants.

Scientific). Skin prick testing was undertaken according to interna-

Clinical reactivity was confirmed at OFC in 69% of participants

tional guidelines using ALK lancets and commercial extracts (ALK-

(and 99% of participants older than 1 year of age). Of these OFC,

Abello) with 1% histamine as a positive control, and the mean wheal

84% were DBPCFC conducted according to PRACTALL consensus.

diameter noted.

The family of an 8-year-old male in the HCSC cohort with a history
of multiple anaphylaxis events to milk (including bronchospasm to a

2.5 | Statistical analyses

small piece of chocolate 1 month prior to the single-dose challenge)
declined OFC, but the child was enrolled in a local oral immunotherapy programme and experience objective symptoms (general-

Analyses were planned prospectively. The proportion of participants

ized urticaria and bronchospasm during updosing), thus confirming

reacting to 0.5 mg cow's milk protein was estimated with 2-sided

clinical reactivity. Eliciting dose at formal OFC to cow's milk in each

exact 95% confidence intervals. Baseline characteristics across co-

cohort is shown in Table 2, and the dose distribution is summarized

horts were compared using Kruskal-Wallis test since the data were

in Figure 1. There were no differences across the cohorts in terms

not normally distributed. Receiver operating characteristic (ROC)

of eliciting dose (P = .29), implying that the 4 cohorts were simi-

curves were generated in order to identify possible predictors for

lar to each other in terms of clinical reactivity. We did not observe

reactivity to 0.5 mg cow's milk protein. A P value of < .05 was consid-

any correlation between age and eliciting dose at formal challenge

ered significant. Assuming a reaction rate of 5% to 0.5 mg cow's milk

(Spearman's r = .05, P = .59).

protein, an overall sample size of 150 and 250 would correspond to
a lower 95% confidence limit of 2.1% and 2.8%, respectively, and an
upper confidence limit of 9.8% and 8.7%, respectively, for the estimated ED 05.

2.6 | Ethical approval

3.1 | Reactions to challenge using 0.5 mg cow's
milk protein
Of the 172 OFC eligible for inclusion, 122 (71%) showed no symptoms (Table 3). A total of 33 (19%) participants reported transient
subjective symptoms, while 17 had objective symptoms, of which

Local approvals were obtained for each clinical centre: Imperial,

12 (7.0%, 95% CI 3.7%-11.9%) met the predetermined challenge-

NHS Human Research Authority reference 15/LO/0286; HCSC,

positive criteria. These reactions are documented in Table 4. One

Ethics Committee reference 14/345; NJH, Ethics Committee refer-

participant, a 17-year-old, experienced mild chest tightness that

ence R0003/17; CUH, reference ECM4(N) 03/06/14 and ECM4(U)

was associated with bilateral wheeze on auscultation and a 25%

04/07/17. Written informed consent was obtained from all partici-

drop in peak expiratory flow rate, and mild truncal erythema;

pants or their legal guardian, and patient assent was obtained where

these symptoms responded to a single dose of intramuscular

appropriate.

adrenaline. Otherwise, reactions were mild and did not require
treatment. There was no difference in the rate of positive reactions to 0.5 mg protein by challenge matrix formulation (P = .42,

3 | R E S U LT S

Fisher's exact test) or challenge design (single-d ose challenge vs

A total of 267 children were screened for inclusion between August

dictors of reactivity to 0.5 mg cow's milk protein using ROC curve

2015 and September 2020, of whom 182 underwent OFC to 0.5 mg

analysis (Table 5).

DBPCFC, P = .24, Fisher's exact test). We did not identify any pre-
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Baseline demographics of participants who underwent single-dose challenge to cow's milk
Ireland

Madrid, Spain

UK

Centre

CUH

HCSC

NJH

Imperial

Overall

Screened

Age <1 y: 65
>1 y: 11

60

64

67

267

Did not meet inclusion criteria for OFC or
refused to participate

13

30

33

9

85

Underwent single-dose challenge

Age < 1 y: 57
>1 y: 6

30

31

58

182

Age (median, IQR)

0.6 y
(0.5-0.7)

5y
(2-6)

9y
(8-12)

11 y
(8-14)

6y
(0.7-11)

Sex (%male)

63%

42%

52%

64%

57%

History of prior anaphylaxisa to cow's milk

6/62
(10%)

8/24
(33%)

17/31
(55%)

29/58
(52%)

60/182
(33%)

Excluded due to tolerance to CMPA at
subsequent OFC

1

6

1

2

10

Total “valid” single-dose challenges

62

24

30

56

172

Positive OFC

11/62
(18%)

21/24
(88%)

30/30
(100%)

56/56
(100%)

118/172
(69%)

Reaction last 2m

51/62
(82%)

3/24
(13%)

n/a

n/a

54/172
(31%)

Cow's Milk (median, IQR)

3.9
(1.2-15.6)

10.8
(1.7-27.6)

20.5
(6.8-87.4)

19.9
(3.0-56.4)

10.3
(2.1-4 3.9)

Casein (median, IQR)

1.0
(0.2-8.3)

2.7
(0.35-21.0)

13.0
(2.7-81.1)

14.2
(2.6-52.0)

6.4
(0.8-27.4)

7 (5-9)

6 (5-7 )

7 (5-8)

7 (5-9)

7 (5-8)

Inclusion criteria

Serum IgE to:

Skin Prick test (mm):
Cow's Milk (median, IQR)

b

5 (3-8)

6 (5-9)

7 (5-9)

6 (4-9)

43 (69%)

13 (62%)

21 (70%)

42 (75%)

119
(70%)

Median

170

1433

444

144

433

IQR (number)

(68-3 40)
(n = 11)

(228-1659)
(n = 21)

(44-4 444)
(n = 30)

(44-1444)
(n = 56)

(76-1659)
(n = 118)

Casein (median, IQR)

n/a

SPT ≥8 mm (or 6mm for patients under 2 y)29
OR sIgE ≥15 kUA/l30
Eliciting dose at formal OFC (mg protein)

a

Anaphylaxis defined as prior cardiovascular or lower respiratory compromise.

b

n/a : casein skin test extract not available in Ireland.

These data therefore broadly validate the estimated ED 05 for

predetermined objective criteria was 7.0% (95% CI 3.7%-11.9%). This

cow's milk of 0.5 mg protein (with potential reactions occurring in

is within the statistical bounds for the original estimated ED 05 of

an interval between 3.7% and 11.9% of the milk-allergic population).

0.5 mg cow's milk protein that would result in 5% of the milk-allergic
population reacting with objective symptoms. These data therefore
imply that proposed ED 05 values greater than 0.5 mg over-estimate

4 | D I S CU S S I O N

the true ED 05 for cow's milk.

Single-dose OFC has previously been used to validate the esti-

try to establish action levels above which measures are required for

mated ED 05 for peanut, derived from statistical dose-distribution

risk management, such as the use of precautionary allergen label-

The use of population EDs has been proposed by the food indus-

3

modelling of individual patient threshold doses. In this study, we

ling. 21 One such scheme is the Voluntary Incidental Trace Allergen

utilized a similar approach to validate proposed ED 05 estimates for

Labelling (VITAL) in Australia. The VITAL Scientific Expert Panel re-

cow's milk. The observed proportion of patients reacting to 0.5 mg

cently updated reference doses for major food allergens, using up-

cow's milk protein (approximately 0.015 mL of fresh cow's milk) with

dated OFC datasets and a new Stacked Model Averaging algorithm

|
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incorporating five different statistical models (Weibull, Log Logistic,
Log Normal, Log Double Exponential, General Pareto).

2,22
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curves may not represent the true allergic population. Importantly,

For cow's

heterogeneity in patients with cow's milk allergy is much more likely

milk protein, an ED 05 of 2.4 mg (95%CI 1.3 to 5.0) was proposed,

to be a confounder compared to other food allergies. This is be-

although the action level was based on an ED 01 of 0.2 mg (95%CI

cause many included subjects may be in a transition towards natural

0.1 to 0.5). Prior to the updated VITAL publication, estimated ED 05

resolution; there is evidence that this dynamic nature of milk allergy

values for cow's milk derived from the analysis of multiple cohorts

in younger children will impact on reaction threshold levels at food

varied from 0.57 mg to 1.9 mg. This variation is mainly due to the

challenge.17 These are the pivotal justifications for single-dose chal-

uncertainty resulting from a lack of data with respect to low-dose

lenges (such as this study) to validate the estimated ED at the lower

reactors, a phenomenon that particularly affects cow's milk OFC. 2

end of the dose distribution curve where data have been lacking,

In the latest analysis by the VITAL Scientific Expert Panel, over 21%

using a patient cohort that includes subjects who are less likely to

of data was left-censored (ie patients with CMPA reacted to the first

outgrow their milk allergy in early childhood.

OFC dose) and 75% of included data were derived from OFC where

It is particularly important to have certainty over EDs used for

the initial dose was >1.5 mg protein (and often significantly more

allergen risk management in CMPA. Cow's milk is increasingly ubiq-

so). 2 In addition, current estimates rely on data from routine clinical

uitous in our diets; its protein fractions are soluble and both (liquid)

challenges where subjects may be excluded (eg due to prior ana-

milk and milk powder tend to distribute well in formulations resulting

phylaxis or recent reaction) and so the resulting dose-distribution

in a homogenous distribution throughout a food product (as opposed
to particulate distribution associated with allergens such as nuts).9,23

100

and can be difficult to eliminate from food production lines (eg those

Published data
based on Stacked
Model Averaging
algorithm23

80

% participants
tolerating dose

It is a frequent cause of severe and even fatal allergic reactions9-14

This study

60

used to produce chocolate-based products) to the extent that a significant proportion of dark chocolate products (made without cow's
milk as an ingredient) contain significant levels of cow's milk protein due to shared production. 23,24 In validating the ED 05 for cow's
milk as 0.5 mg protein, these data indicate that current estimates

40

for ED 05 for cow's milk based on population modelling using existing
data are too high. Additional, larger challenge data sets (based on

20

dosing schedules that would allow for interval censoring) are needed

n=118

0

1

to provide more precision to the population dose-distribution mod-

10

100

elling around lower ED values.

1000

These data are also relevant to the selection of appropriate pro-

Tolerated dose

tocols for clinical challenges to diagnosis CMPA. In general, the initial
doses recommended for DBPCFC under the PRACTALL consensus

F I G U R E 1 Threshold dose distribution for the 118 participants
who also underwent formal food challenge to cow's milk, compared
to published dose-distribution data by Houben et al22 Error bars
represent 95% confidence intervals [Colour figure can be viewed at
wileyonlinelibrary.com]

are 3 mg protein,6 which for most allergens will tend to cause objective symptoms in around 10% of individuals (ED10).1,7 If the ED 05
for cow's milk is closer to 0.5 mg, then well over 10% of individuals
with CMPA would be expected to react to an initial dose of 3 mg.

TA B L E 3 Symptoms experienced to
single-dose challenge to cow's milk

Ireland

Madrid, Spain

UK

Overall

Centre

CUH

HCSC

NJH

Imperial

Eligible participants
(completed OFC)

62

24

30

56

172

No symptoms

54

22

18

28

122

Transient subjective
symptoms only

n/ab

0

10

23

33

8

2

2

5

17

8

0

1

3

12

0

0

0

1

1

Outcome:

Any objective symptoms
Objective symptoms
Anaphylaxis
a

a

Objective symptoms which met predefined criteria.

b

Due to participant age, it was not possible to observe study-defined subjective symptoms in the
majority of participants at CUH.
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Participants who met the predetermined objective reactivity criteria/case definition
SPT to CM
extract
(mm)

sIgE to CM
(kUA/l)

Time to
symptoms

Challenge Symptoms

ID

Centre

Age
(y)

Ui-14

CUH

0.9

F

Recent reaction in last
2m and sensitised

5

15.4

<5 mins

Vomiting

Ui-4 0

CUH

1.3

F

Recent reaction in last
2m and sensitized

4

3.2

15-20 mins

Urticaria, lip
angioedema, eczema
flare

Ui-66

CUH

2.6

M

Recent reaction in last
2m and sensitized

5

0.95

<5 mins

Periorbital angioedema,
abdominal pain,
eczema flare

Sex

Inclusion

Ui-72

CUH

0.2

F

Positive formal OFC

3

7.8

<5 mins

Vomiting

U1-26

CUH

0.5

M

Recent reaction in last
2m and sensitized

6

1.36

5-10 mins

Lip angioedema,
urticaria

U1-29

CUH

0.9

M

Recent reaction in last
2m and sensitized

5

4.42

5-10 mins

Urticaria

U1-36

CUH

0.7

M

Recent reaction in last
2m and sensitized

6

ND

5-10 mins

Urticaria

U1-50

CUH

0.4

M

Recent reaction and
sensitized

5

1.48

5-10 mins

Urticaria

S101

Imperial

17

F

Positive DBPCFC

12

29.6

<5 mins

Bilateral wheeze,
erythema

S129

Imperial

14

F

Positive DBPCFC

13

>100

38 mins

Persistent
rhinoconjunctivitis

S155

Imperial

10

F

Positive DBPCFC

11

80.4

24 mins

Lip angioedema,
oropharyngeal pruritus

S214

NJH

8

M

Positive DBPCFC

9

83.4

15 mins

Persistent dry cough,
vocal hoarseness

Abbreviation: ND, not done due to insufficient blood sample.

TA B L E 5 Predictors of reactivity to single-dose challenge of
0.5 mg cow's milk protein
Biomarker

Area under ROC
curve

P
value

sIgE to cow's milk

0.50

.98

sIgE to casein

0.57

.56

SPT to cow's milk extract

0.55

.57

SPT to casein

0.54

.76

true clinical reactivity (including by OFC in 67%, of which 84% were
DBPCFC) are strengths of this study. Infants in one of the Cork cohorts underwent challenges using liquid milk rather than milk powder; however, the estimated EDs for liquid milk and milk powder are
equivalent.7 We chose to recruit a significant proportion of participants under 1 year of age, since CMPA is more prevalent in this age
group, but also included teenagers with persistent CMPA who are
often excluded from challenge studies. It is possible that very young
children with CMPA are more likely to outgrow this allergy and this
may be reflected in eliciting doses at challenge. However, we did

Furthermore, many challenge protocols used in clinical practice start

not identify any differences across the included cohorts in terms of

with higher doses of 1 mL cow's milk (approximately 30 mg pro-

eliciting dose, although the number of very young children in this

tein), 25,26 to which around 25% of allergic individuals will react. In

subanalysis was limited.

the context of OFC where patients may have a higher likelihood of

To minimize selection bias, we utilized a recruitment strategy that

clinical reactivity (eg prior to commencing allergen immunotherapy),

did not involve the subjective selection of participants by healthcare

clinicians might therefore wish to choose a lower initial challenge

professionals, nor did we exclude participants with a history of ana-

dose to which objective symptoms are unlikely (eg to build confi-

phylaxis. Furthermore, the distribution of eliciting doses at challenge

dence in the patient and their family).

in this study (as depicted in Figure 1) is not dissimilar to published
data for cow's milk, 22 which strongly supports our assessment that

4.1 | Strengths and limitations of this study

our participants are very likely to represent the population with
CMPA in Europe. We were unable to determine the proportion of
subjects with tolerance to baked milk, as this had not been assessed

The international collaboration, robust protocol and the use of pre-

in the majority of subjects. In any event, data suggest that eliciting

determined objective, challenge-positive criteria to demonstrate

doses in individuals with or without tolerance to the baked allergen

|
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do not differ significantly. 27 While there are some very limited data

FAES Pharma, Aimmune Therapeutics and LETI Pharma. PRR reports

to indicate that adults with CMPA may have a higher threshold than

funding from the Health Research Fund of Carlos III Health Institute,

children (on the basis of OFC data from 25 adults and 323 children),1

Foundation for Biomedical Research of the Niño Jesus University

we did not identify an age-dependent effect amongst the partici-

Children's Hospital and Spanish Society of Allergology and Clinical

pants recruited in this study.

Immunology Foundation and reports honoraria for consultancy and/

Just over half of the single-dose OFC were undertaken using a

or advisory board and/or lectures from ALK-Abello, FAES Pharma,

double-blind methodology, with the 0.5 mg dose constituting the

LETI Pharma, Merck, Aimmune Therapeutics, Allergy Therapeutics,

first dose at DBPCFC (with prolonged observation interval prior to

MEDA Pharma and NovartisDC participated to lectures and boards for

the 2nd dose being administered). We did not observe a significant

Aimmune. MVO reports research funding from the Health Research

difference in frequency of objective reaction to 0.5 mg cow's milk

Fund of Carlos III Health Institute (Spain), European Commission

protein between those who underwent an open challenge and those

Horizon 2020, FPIES Foundation, Spanish Society of Allergology and

who had DBPCFC. Two subjects who underwent DBPCFC reacted

Clinical Immunology and Spanish Society of Paediatric Allergology,

with objective symptoms in the 2 hours following the 0.5 mg dose:

Asthma and Clinical Immunology. JLB has received consultancy fees

one had no symptoms whatsoever to the 0.5 mg dose, but rapidly

from DBV Technologies and Taylor Consulting LLC; is employed by

developed objective symptoms to the next dose administered; the

the University of Nebraska; has received research support from the

second had subjective symptoms that completely resolved for at

United States Department of Agriculture (USDA)-National Institute of

least 60 minutes prior to the next dose administered. Given these

Food and Agriculture (NIFA) and Nima; and receives royalties from

observations and published data that reactions to cow's milk occur

Neogen Corp. RvR reports personal fees from HAL Allergy BV, Citeq

more rapidly than for other allergens, 28 it is very unlikely that the re-

BV, Angany In., and Thermo Fisher Scientific. ENCM reports grants

actions in these 2 participants were due to the 0.5 mg dose. Finally,

from the UK Biological and Biotechnological Sciences Research

these data apply to challenge conditions, where allergic individuals

Council, DBV Technologies, Reacta Biotech, the Medical Research

are clinically well and usually without the presence of co-factors,

Council, the European Union and the UK Food Standards Agency and

which might impact on reaction thresholds. Our aim in this study

has patents pending to Reacta Biotech Ltd (PCT/GB2016/051637

was not to assess the risk of participants reacting to 0.5 mg doses

and PCT/GB2016/053829). MFR reports research grants from

due to the presence of co-factors.

Spanish Government (MINECO, ISCIII), and grants to institution
from Aimmune, ALK and Diater; consultancy fees from Aimmune,

5 | CO N C LU S I O N S

DBV, Novartis, SPRIM; and lecture fees from Aimmune, Allergy
Therapeutics, Diater, HAL Allergy. JO’BH receives research funding
and consultancy fees from Aimmune Therapeutics, research funding

In summary, we have demonstrated that the ED 05 for cow's milk is

from DBV Technologies, Johnson & Johnson. All other authors de-

likely to be around 0.5 mg protein and certainly lower than some

clare no competing interests.

of the proposed values for ED 05 in the literature. These data demonstrate the need to validate estimated ED values derived from
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